MAFLD与卒中关联在CKD患者中更强:开滦队列研究
基于开滦队列95,353名参与者的前瞻性研究,中位随访12.8年,MAFLD在CKD患者中与卒中风险升高相关(HR 1.34),而在无CKD者中无显著关联(HR 1.05),交互作用P<0.001。该关联主要见于缺血性卒中,MAFLD与全因死亡无显著关联。
要点
- CKD患者中MAFLD与卒中风险升高相关(HR 1.34),无CKD者无显著关联(HR 1.05)。
- MAFLD与缺血性卒中相关(HR 1.38),与出血性卒中无显著关联(HR 1.04)。
- CKD患者中MAFLD合并糖尿病或超重/肥胖时卒中风险更高,无超重/肥胖或糖尿病时无显著关联。
核心结论
- MAFLD在CKD患者中与卒中风险升高相关,在无CKD者中无显著关联,交互作用P<0.001。
- MAFLD与全因死亡在CKD和无CKD患者中均无显著关联。
研究设计与样本
- 前瞻性队列研究,纳入开滦队列95,353名参与者,其中35,749名基线或随访期间有CKD,59,604名无CKD。
- 中位随访12.8年,发生卒中6,140例(6.4%),全因死亡11,975例(12.6%)。
主要发现
- CKD患者中MAFLD与卒中风险升高相关(HR 1.34,95% CI 1.23-1.45),无CKD者无显著关联(HR 1.05,95% CI 0.97-1.15)。
- CKD患者中MAFLD与缺血性卒中相关(HR 1.38,95% CI 1.26-1.51),与出血性卒中无显著关联(HR 1.04,95% CI 0.85-1.26)。
- CKD患者中MAFLD与全因死亡无显著关联(HR 1.04,95% CI 0.98-1.10),无CKD者亦无显著关联(HR 1.03,95% CI 0.97-1.09)。
- CKD患者中,MAFLD合并糖尿病者卒中风险HR 1.36(95% CI 1.23-1.50),合并超重/肥胖者HR 1.30(95% CI 1.14-1.50),无超重/肥胖或糖尿病者无显著关联(HR 1.08,95% CI 0.81-1.43)。
临床怎么用
- 在CKD患者中应关注MAFLD的存在,尤其合并糖尿病或超重/肥胖时,其与卒中风险升高相关。
局限性
- 本研究为观察性研究,且纳入的CKD患者估算肾小球滤过率相对较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
RATIONALE & OBJECTIVE: Metabolic dysfunction-associated fatty liver disease (MAFLD), a risk factor for stroke and all-cause mortality, is highly prevalent among patients with chronic kidney disease (CKD), but it is unclear whether the association of MAFLD with stroke and all-cause mortality differs within and outside of the setting of CKD. STUDY DESIGN: Prospective cohort study. SETTING & PARTICIPANTS: We enrolled 95,353 participants from the Kailuan Cohort Study, among whom 35,749 had CKD at baseline or developed CKD during the follow-up period, and 59,604 individuals who had no CKD at baseline or during the follow-up period. EXPOSURE: MAFLD. OUTCOME: Stroke (ischemic stroke, hemorrhagic stroke), all-cause mortality. ANALYTICAL APPROACH: Adjusted Cox regression models were used to estimate the influence of MAFLD on stroke outcomes within the subgroups defined by the presence of CKD. RESULTS: After a median follow-up of 12.8 years, 6,140 strokes (6.4%) and 11,975 deaths from any cause (12.6%) occurred. After adjusting for potential confounders, MAFLD was associated with an increased incidence of stroke among the participants with CKD (HR, 1.34 [95% CI, 1.23-1.45]) but not among those without CKD (HR, 1.05 [95% CI, 0.97-1.15]; Pinteraction<0.001). This association was principally related to ischemic stroke (HR, 1.38 [95% CI, 1.26-1.51]) and not hemorrhagic stroke (HR, 1.04 [95% CI, 0.85-1.26]). No association was found between MAFLD and all-cause mortality in the participants with CKD (HR,1.04 [95% CI, 0.98-1.10]) or those without CKD (HR,1.03 [95% CI, 0.97-1.09]). Among the participants with CKD, compared with non-MAFLD, MAFLD with diabetes (HR,1.36 [95% CI, 1.23-1.50]) or overweight/obesity (HR,1.30 [95% CI, 1.14-1.50]) was associated with a higher risk of stroke whereas MAFLD without overweight/obesity or diabetes was not associated with a higher risk (HR,1.08 [95% CI, 0.81-1.43]). LIMITATIONS: This was an observational study and included individuals with CKD who had a relatively high estimated glomerular filtration rate. CONCLUSIONS: MAFLD was associated with an increased risk of stroke in individuals with CKD but not in those without CKD. PLAIN-LANGUAGE SUMMARY: Metabolic dysfunction-associated fatty liver disease (MAFLD), which is recognized as a risk factor for stroke in the general population, is highly prevalent among individuals with chronic kidney disease (CKD). However, the impact of MAFLD on the risk of stroke in patients with CKD remains uncertain. We investigated the association of MAFLD with stroke in individuals with and without CKD. Our analysis revealed that MAFLD was associated with a significantly increased risk of stroke in individuals with CKD, and the magnitude of this increased risk was greater in the setting of CKD. These findings highlight the need for increased attention to MAFLD in patients with CKD and emphasize that addressing and preventing MAFLD in this population may contribute to reduced morbidity from stroke.
引用
- Li Y, Wu S, Gao J, et al. Association of Stroke With Metabolic Dysfunction-Associated Fatty Liver Disease With and Without CKD. Am J Kidney Dis. 2023. PMID: 37838141. doi:10.1053/j.ajkd.2023.08.016
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。